Ribon Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics that target stress support pathways activated under cellular stress conditions, specifically in cancer and inflammation. Their lead program, RBN-2397, is a PARP7 inhibitor in clinical development for treating solid tumors, including lung cancer.